-->

Tag: Breast Cancer Recurrence Prevention

Home / Breast Cancer Recurrence Prevention

Categories

Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack is approved by the USFDA for early high-risk breast cancer

On September 17, 2024, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in conjunction with an aromatase inhibitor for the adjuvant therapy of adult...
breast-cancer-recurrence-prevention

segmental mastectomy in malignant lesions


breast-cancer-recurrence-prevention

Scan the code